Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy

Pediatric Neurosurgery

Volumn 25, Issue 4, 1996, Pages 174-181

  Prados, Michael D ^a   Warn, William ^a   Edwards, Michael S B ^a   Ater, Joann ^b   Rabbit, Jane ^a   Lainborn, Kathleen ^a   Davis, Richard ^a   Levin, Victor A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Medulloblastoma; Primitive neuroectodermal tumors of the CNS; Radiation therapy

Indexed keywords

HYDROXYUREA; LOMUSTINE; MITOLACTOL; NITROSOUREA DERIVATIVE; PROCARBAZINE; TIOGUANINE; VINCRISTINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; THROMBOCYTOPENIA;

EID: 0030389709     PISSN: 10162291     EISSN: 14230305     Source Type: Journal    
DOI: 10.1159/000121120     Document Type: Article

References (20)

1. Tait DM, Thomton-Johnes J, Bloom HJG, Lemerle J, Morris-Jones P: Adjuvant chemotherapy for medulloblastoma: The first multicentre control trial of the International Society of Paediatric Oncology (SIOP). Eur J Cancer 1990;26:464-469.
2. Evans AC, Jenkin RDT, Sposto R, Orgcga JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, Hammond GD: The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-582.
3. Fujimoto S, Ogawa M, Sakurai Y: Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-l-(2-chlorocthyl)-l-nitrosourea hydrochloride. Cancer Res 1984:42:4079-4085.
4. Bodell WJ, Morgan WF, Williams ME, Deen DF: Potentiation of 1,3-bis(2-chloroethyl)-1-ni-trosourea (BCNU)-induccd cytotoxicity in 9L cells by pretreatment with 6-thioguanine. Bio-chem Pharmacol 1985;34:515-520.
5. Hunter KJ, Deen DF, Marton LJ: Differential response to 1,3-bis (2-chloroethyl)-l-nitrosourea in drug-resistant and-sensitive 9L rat brain tumor cells pretreated with a-di-fluoromethylomithine and 6-thioguanine. Int J Cancer 1989;44:658-660.
6. Weinkam RJ, Shiba DA: Metabolic activation of procarbazine. Life Sci 1978;22:937-945.
7. Zlotogorski C, Erickson LC: Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloro-ethylnitrosourca to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis 1983;4:759-763.
8. Institoris E: DNA alkylation sites and cytotoxicity in Yoshida cells treated with bifunctional galactitols; in Petri P, Grassi GG (eds): Current Chemotherapy and Immunotherapy. Washington, American Society of Microbiology, 1982, pp 1378-1380.
9. Lapis K, Jeney A, Köpper L, Szende B, Takacs J: Theoretical basis for designing combination therapy with dibromodulcitol; in Heilman K, Connors TA (cds): Cancer Chemotherapy. New York, Plenum Press, 1976, pp 37-42.
10. Levin VA, Wilson CB: Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. Cancer Chemother Pharmacol 1978; 1: 41-48.
11. Levin VA, Rodriguez LA, Edwards MS, Wara WM, Liu H-C, Fulton D, Davis RL, Wilson CB, Silver P: Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. J Neurosurg 1988;68:383-387.
12. Boyett J, Zeltzer P, Finlay J, Albright L, Wisoff J, Geyer JR, McGuire P, Allen J, Rorke L, Stanley P, Stehbens J, Stevens K, Shurin S, Milstein J, Li H, Packer R, Bleyer A: Progression-free survival and risk factors for primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) in children: Report of the Children’s Cancer Group (CCG) randomized trial, CCG 921. Proc Am Soc Clin Oncol 1995; 14:147.
13. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’Angio G, Wechsler-Jentzsch K, Reaman G, Cohen B, Bruce DA, Rorke LB, Molloy P, Ryan J, LaFond D, Evans AE, Schut L: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-698.
14. Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, Phillips A, Neidhardt MK: Prospective randomized trial of chemotherapy given before radiotherapy in childhood medul-loblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pe-diatr Oncol 1995;25:166-178.
15. Crafts DC, Levin VA, Edwards MSB, et al: Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J Neurosurg 1978;49:589-592.
16. Levin VA, Edwards MSB, Gutin PH, Vestnys P, Fulton D, Seager M, Wilson CB: Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. J Neurosurg 1984; 61:1063-1068.
17. Lefkowitz IB, Packer RJ, Siegel KR, Sutton LN, Schut L, Evans AE: Results of treatment of children with recurrent medulloblastoma/ primitive neuroectodermal tumors with lomus-tine, cisplatin, and vincristine. Cancer 1990; 65:412-417.
18. Deutsch M, Thomas P, Boyett J, et al: Low-stage medulloblastoma: A Children’s Cancer Study Group (CCSG) and Pediatric Oncology Group (POG) randomized study of standard versus reduced neuroaxis irradiation. Proc Am Soc Clin Oncol 1991; 10:124.
19. Goldwcin J W, Radcliffe J, Johnson J, Moshang T, Packer RJ, Sutton LN, Rorke LB, D’Angio GJ: Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996,34:899-904.
20. Haiberg FE, Wara WM, Fippin LF, Edwards MSB, Levin VA, Davis RL, Prados MD, Wilson CB: Low-dose craniospinal radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 1991;20:651-654.